WO2000049166A3 - Production of helper dependent adenovirus vectors based on use of endonucleases - Google Patents

Production of helper dependent adenovirus vectors based on use of endonucleases Download PDF

Info

Publication number
WO2000049166A3
WO2000049166A3 PCT/US2000/003771 US0003771W WO0049166A3 WO 2000049166 A3 WO2000049166 A3 WO 2000049166A3 US 0003771 W US0003771 W US 0003771W WO 0049166 A3 WO0049166 A3 WO 0049166A3
Authority
WO
WIPO (PCT)
Prior art keywords
helper
adenovirus vectors
helper dependent
endonucleases
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/003771
Other languages
French (fr)
Other versions
WO2000049166A2 (en
Inventor
Frank L Graham
Philip Ng
Robin Parks
Silvia Bacchetti
Mauro Anglana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to CA002363061A priority Critical patent/CA2363061A1/en
Priority to EP00913460A priority patent/EP1157103A2/en
Priority to JP2000599890A priority patent/JP2004501602A/en
Priority to AU34907/00A priority patent/AU769735B2/en
Publication of WO2000049166A2 publication Critical patent/WO2000049166A2/en
Publication of WO2000049166A3 publication Critical patent/WO2000049166A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or HDVs) from which all or most of the viral genes have been removed. The vector system described herein is a new method designed to eliminate helper viruses from the final HDV preparation by cleavage of the helper virus DNA with an endonuclease, alone or in combination with other methods known to limit the level of helper virus contamination of helper dependent vector preparations. The disclosed methods and compositions also provide for regulated control of gene expression.
PCT/US2000/003771 1999-02-18 2000-02-15 Production of helper dependent adenovirus vectors based on use of endonucleases Ceased WO2000049166A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002363061A CA2363061A1 (en) 1999-02-18 2000-02-15 Production of helper dependent adenovirus vectors based on use of endonucleases
EP00913460A EP1157103A2 (en) 1999-02-18 2000-02-15 Production of helper dependent adenovirus vectors based on use of endonucleases
JP2000599890A JP2004501602A (en) 1999-02-18 2000-02-15 System for the production of helper-dependent adenovirus vectors based on the use of endonuclease
AU34907/00A AU769735B2 (en) 1999-02-18 2000-02-15 A system for production of helper dependent adenovirus vectors based on use of endonucleases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25092999A 1999-02-18 1999-02-18
US09/250,929 1999-02-18
US47581399A 1999-12-30 1999-12-30
US09/475,813 1999-12-30

Publications (2)

Publication Number Publication Date
WO2000049166A2 WO2000049166A2 (en) 2000-08-24
WO2000049166A3 true WO2000049166A3 (en) 2001-04-12

Family

ID=26941253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003771 Ceased WO2000049166A2 (en) 1999-02-18 2000-02-15 Production of helper dependent adenovirus vectors based on use of endonucleases

Country Status (6)

Country Link
US (1) US20070014769A1 (en)
EP (1) EP1157103A2 (en)
JP (1) JP2004501602A (en)
AU (1) AU769735B2 (en)
CA (1) CA2363061A1 (en)
WO (1) WO2000049166A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006886A1 (en) * 2000-02-16 2001-08-23 Hepavec Ag Fuer Gentherapie Non-human helper dependent virus vector
EP1379281A4 (en) * 2001-03-26 2005-05-18 Univ Leland Stanford Junior SYSTEM OF ADENOVIRAL VECTORS DEPENDENT OF AN AUXILIARY, AND METHODS OF USE
ES2337973B8 (en) * 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. ADENOVIRUS AUXILIARY SELF-INACTIVANTS FOR THE PRODUCTION OF ADENOVIRUS RECOMBINANTS OF HIGH CAPACITY.
ES2330826B1 (en) * 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. HIGH CAPACITY ADENOVIRUS PACKING SYSTEM.
JP6114530B2 (en) * 2012-10-16 2017-04-12 ルネサスエレクトロニクス株式会社 Display device and display device driver

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014408A2 (en) * 1994-11-07 1996-05-17 Institut Pasteur Nucleotide sequence encoding the enzyme i-scei and the uses thereof
WO1996040955A1 (en) * 1995-06-07 1996-12-19 Graham Frank L Adenovirus vectors for gene therapy
WO1998013510A1 (en) * 1996-09-25 1998-04-02 Graham Frank L Improved adenovirus vectors generated from helper viruses and helper-dependent vectors
WO1999002647A2 (en) * 1997-07-10 1999-01-21 Hepavec Ag Für Gentherapie Cloning vectors for producing adenoviral minimal viruses
EP0919624A2 (en) * 1993-05-28 1999-06-02 Transgene S.A. Defective Adenoviruses and corresponding transcomplementant celllines
WO1999053085A2 (en) * 1998-04-15 1999-10-21 The Research Foundation Of State University Of New York Selective regulation of adenovirus production
WO1999061638A1 (en) * 1998-05-27 1999-12-02 Transgene S.A. Chimeric adenoviral vectors
US6001557A (en) * 1994-10-28 1999-12-14 The Trustees Of The University Of Pennsylvania Adenovirus and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4920211A (en) * 1988-01-04 1990-04-24 Vanderbilt University Mutated adenovirus E1A gene for E1A promoter stimulation
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5474896A (en) * 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5849553A (en) * 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
FR2730504B1 (en) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF RECOMBINANT ADENOVIRUS GENOMES
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919624A2 (en) * 1993-05-28 1999-06-02 Transgene S.A. Defective Adenoviruses and corresponding transcomplementant celllines
US6001557A (en) * 1994-10-28 1999-12-14 The Trustees Of The University Of Pennsylvania Adenovirus and methods of use thereof
WO1996014408A2 (en) * 1994-11-07 1996-05-17 Institut Pasteur Nucleotide sequence encoding the enzyme i-scei and the uses thereof
WO1996040955A1 (en) * 1995-06-07 1996-12-19 Graham Frank L Adenovirus vectors for gene therapy
WO1998013510A1 (en) * 1996-09-25 1998-04-02 Graham Frank L Improved adenovirus vectors generated from helper viruses and helper-dependent vectors
WO1999002647A2 (en) * 1997-07-10 1999-01-21 Hepavec Ag Für Gentherapie Cloning vectors for producing adenoviral minimal viruses
WO1999053085A2 (en) * 1998-04-15 1999-10-21 The Research Foundation Of State University Of New York Selective regulation of adenovirus production
WO1999061638A1 (en) * 1998-05-27 1999-12-02 Transgene S.A. Chimeric adenoviral vectors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANGLANA MAURO ET AL: "Construction of a recombinant adenovirus for efficient delivery of the I-SceI yeast endonuclease to human cells and its application in the in vivo cleavage of chromosomes to expose new potential telomeres.", NUCLEIC ACIDS RESEARCH, vol. 27, no. 21, 1 November 1999 (1999-11-01), pages 4276 - 4281, XP002155138, ISSN: 0305-1048 *
KANEGAE Y ET AL: "EFFICIENT GENE ACTIVATION IN MAMMALIAN CELLS BY USING RECOMBINANT ADENOVIRUS EXPRESSING SITE-SPECIFIC CRE RECOMBINASE", NUCLEIC ACIDS RESEARCH,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 23, no. 19, 11 October 1995 (1995-10-11), pages 3816 - 3821, XP002006337, ISSN: 0305-1048 *
NICOLAS ANDREA L ET AL: "Creation and repair of specific DNA double-strand breaks in vivo following infection with adenovirus vectors expressing Saccharomyces cerevisiae HO endonuclease.", VIROLOGY, vol. 266, no. 1, 5 January 2000 (2000-01-05), pages 211 - 224, XP002155139, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
JP2004501602A (en) 2004-01-22
AU3490700A (en) 2000-09-04
US20070014769A1 (en) 2007-01-18
EP1157103A2 (en) 2001-11-28
WO2000049166A2 (en) 2000-08-24
AU769735B2 (en) 2004-02-05
CA2363061A1 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
Berkner et al. Generation of adenovirus by transfection of plasmids
WO1998036779A3 (en) System for the in vivo delivery and expression of heterologous genes in the bone marrow
EP1437400A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
ATE210727T1 (en) ATTENUATED VACCINE AND GENETIC TRANSFERASE VIRUS, METHOD FOR PRODUCING THEREOF AND MEDICINAL PRODUCT CONTAINING IT
CN102740881A (en) Method for orthopoxvirus production and purification
CA2321964A1 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
CN104812894B (en) Novel MVA virus and its use
AUPN477695A0 (en) Gene therapy
CA2428073A1 (en) Paramyxovirus vector for gene transfer to the cardiovascular system
MX2012000979A (en) Enzymatic composition for the digestion of chicken embryos.
JP2011234731A (en) Vector for integration of heterologous sequence into poxviral genome
CN103757053A (en) Site-specific modification and screening method for specific DNA (deoxyribonucleic acid) viral genome
Yuan et al. A simple and efficient approach to construct mutant vaccinia virus vectors
CA2089484A1 (en) Method for modifying the cell tissue or host tropism of a microorganism; recombinant microorganisms obtained in this way and use thereof in medicine and veterinary medicine
Moraes et al. pAd5-Blue: direct ligation system for engineering recombinant adenovirus constructs
Volkening et al. Purification of DNA from the cell-associated herpesvirus Marek's disease virus for 454 pyrosequencing using micrococcal nuclease digestion and polyethylene glycol precipitation
Denoya et al. Foot and mouth disease virus II. Endoribonuclease activity within purified virions
JP2002519068A5 (en)
WO2002000924A3 (en) Viral phospholipase a2 enzymes, anti-viral agents and methods of use
HUP0200320A2 (en) Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof
EP0261925B1 (en) Gene for a-type inclusion body of poxvirus, its preparation and use
Poddar et al. Type I topoisomerase activity after infection of enucleated, synchronized mouse L cells by vaccinia virus
CN106957820B (en) Culture medium, kit and application for telomere extension and proliferation culture of chondrocytes in vitro
US7348178B1 (en) Recombinant adenoviral vector system
WO2001066150A3 (en) Highly efficient gene transfer into human repopulating stem cel ls by rd114 pseudotyped retroviral vector particles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref country code: CA

Ref document number: 2363061

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 599890

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 34907/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000913460

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000913460

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2363061

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2000913460

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 34907/00

Country of ref document: AU